Work

First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses.

Year: 2025

Type: article

Study design: Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.e16232

Authors: Ming Zhao, Ning Lyu, Junzhe Yi, Jiongliang Wang, Xintong Wu, Xiongying Jiang, Song Chen, Jie Xu, Jibin Li, Suixing Zhong, Qi-Feng Chen, Yue Hu, YiMin Zhang, Yujia Song, Genjun Tan, Yunan Zhang

Institutions: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Sun Yat-sen University

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: AstraZeneca

OpenAlex ID: W4410814162

FWCI:

Cites:

Cited by:

Related to: 10